News | April 28, 2026
From losses to lift-off: Astec gains ground in Q4 FY26
The company reported consolidated total income of Rs. 161.3 crore in Q4 FY26, a strong jump from Rs. 120.3 crore in the same period last year
The company reported consolidated total income of Rs. 161.3 crore in Q4 FY26, a strong jump from Rs. 120.3 crore in the same period last year
Deploys $40 million in Hyderabad; advances APIs, peptides, and global small molecule capabilities
_256_384.jpg)
The approval makes Cipla’s product the first AB-rated generic therapeutic equivalent of Ventolin HFA
The webinar series will showcase next-gen imaging technologies, global expert insights, and hands-on sessions on microscopy innovations
Profitability came under strain. Gross profit fell to EUR 246m, with margins narrowing to 23.7% as negative product mix—particularly in Asia Pacific—weighed on performance
Three-day programme focuses on advanced socket design, myoelectric technology and clinical skill development
CLIRNET plans to expand globally and improve how medical knowledge is shared and used in practice
The deal the group says marks a decisive push deeper into severe infectious diseases and the build-out of a global specialty pharmaceuticals platform
A decision is expected by August 17, 2026 under the Prescription Drug User Fee Act timeline
Inspection outcome reinforces company's compliance track record and strengthens its ability to serve regulated markets including the United States
Subscribe To Our Newsletter & Stay Updated
